Comparative Pharmacology
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE versus EDROPHONIUM CHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE versus EDROPHONIUM CHLORIDE PRESERVATIVE FREE.
EDROPHONIUM CHLORIDE vs EDROPHONIUM CHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, prolonging acetylcholine action at neuromuscular junction and autonomic ganglia.
Inhibits acetylcholinesterase, prolonging the action of acetylcholine at nicotinic and muscarinic receptors, enhancing neuromuscular transmission.
10 mg IV bolus, may repeat up to total 10 mg. For myasthenia gravis diagnosis: 2 mg IV test dose, then 8 mg IV if no reaction after 45 seconds.
2 mg intravenous (IV) or intramuscular (IM) as a test dose; for myasthenia gravis diagnosis: 2 mg IV test dose followed by 8 mg IV after 30 seconds if no reaction; for myasthenic crisis: 2 mg IV; for reversal of nondepolarizing neuromuscular blockade: 0.5-1 mg/kg IV.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours; in anephric patients, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Terminal elimination half-life is 1-2 hours in healthy adults; prolonged up to 4-6 hours in renal impairment.
Primarily renal excretion as unchanged drug (approximately 70-80% within 4 hours); minor biliary/fecal elimination accounts for <10%.
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary excretion (10-15%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor